$XLRN ACCELERON PHARMA INC Insider Trading Week 45/2014
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ACCELERON PHARMA INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in ACCELERON PHARMA INC in week 45/2014.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 7.12 | 1,899 | 13,521 | 7,031 | |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.88 | 3,101 | 18,234 | 9,399 | |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 33.60 | 3,043 | 102,245 | 0 | 3 K to 0 (-100.00 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 32.42 | 1,957 | 63,446 | 3,043 | 5 K to 3 K (-39.14 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 7.12 | 1,899 | 13,521 | 5,000 | 3.1 K to 5 K (+61.24 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.88 | 3,101 | 18,234 | 3,101 | 0 to 3.1 K |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.28 | 5,000 | 26,400 | 16,500 | |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 5,000 | 29,400 | 1,500 | |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 4,000 | 23,520 | 14,500 | |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 35.00 | 12,000 | 420,000 | 27,890 | 39.9 K to 27.9 K (-30.08 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.28 | 5,000 | 26,400 | 39,890 | 34.9 K to 39.9 K (+14.33 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 5,000 | 29,400 | 34,890 | 29.9 K to 34.9 K (+16.73 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 33.56 | 2,400 | 80,544 | 29,890 | 32.3 K to 29.9 K (-7.43 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 32.46 | 1,600 | 51,936 | 32,290 | 33.9 K to 32.3 K (-4.72 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 4,000 | 23,520 | 33,890 | 29.9 K to 33.9 K (+13.38 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Option Exercise | M | 5.08 | 1,504 | 7,640 | 33,496 | |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Option Exercise | M | 1.80 | 2,414 | 4,345 | 0 | |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 33.70 | 400 | 13,480 | 23,500 | 23.9 K to 23.5 K (-1.67 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 32.64 | 600 | 19,584 | 23,900 | 24.5 K to 23.9 K (-2.45 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 33.59 | 2,317 | 77,828 | 19,940 | 22.3 K to 19.9 K (-10.41 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 32.43 | 1,601 | 51,920 | 22,257 | 23.9 K to 22.3 K (-6.71 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Buy | M | 5.08 | 1,504 | 7,640 | 23,858 | 22.4 K to 23.9 K (+6.73 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Buy | M | 1.80 | 2,414 | 4,345 | 22,354 | 19.9 K to 22.4 K (+12.11 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 10,000 | 38,800 | 135,751 | |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 33.58 | 3,138 | 105,374 | 10,000 | 13.1 K to 10 K (-23.88 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 32.39 | 1,862 | 60,310 | 13,138 | 15 K to 13.1 K (-12.41 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 33.60 | 3,050 | 102,480 | 15,000 | 18.1 K to 15 K (-16.90 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 32.44 | 1,950 | 63,258 | 18,050 | 20 K to 18.1 K (-9.75 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 10,000 | 38,800 | 20,000 | 10 K to 20 K (+100.00 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 5.08 | 5,000 | 25,400 | 8,750 | |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 0.92 | 313 | 288 | 2,031 | |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 0.92 | 4,687 | 4,312 | 0 | |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 33.60 | 2,964 | 99,590 | 52,656 | 55.6 K to 52.7 K (-5.33 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 32.45 | 2,036 | 66,068 | 55,620 | 57.7 K to 55.6 K (-3.53 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 5.08 | 5,000 | 25,400 | 57,656 | 52.7 K to 57.7 K (+9.50 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 33.62 | 2,935 | 98,675 | 52,656 | 55.6 K to 52.7 K (-5.28 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 32.48 | 2,065 | 67,071 | 55,591 | 57.7 K to 55.6 K (-3.58 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 0.92 | 313 | 288 | 57,656 | 57.3 K to 57.7 K (+0.55 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 0.92 | 4,687 | 4,312 | 57,343 | 52.7 K to 57.3 K (+8.90 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 33.57 | 9,399 | 315,524 | 96,500 | 105.9 K to 96.5 K (-8.88 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 32.57 | 10,601 | 345,275 | 105,899 | 116.5 K to 105.9 K (-9.10 %) |